Premium
Treatment of disseminated paraganglioma with gemcitabine and docetaxel
Author(s) -
Mora Jaume,
Cruz Ofelia,
Parareda Andreu,
Sola Teresa,
de Torres Carmen
Publication year - 2009
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22006
Subject(s) - docetaxel , medicine , gemcitabine , paraganglioma , chemotherapy , oncology , limiting , surgery , mechanical engineering , engineering
A male with metastatic paraganglioma received different chemotherapy regimens and 14 arterial embolizations with no or short‐lasting clinical benefit. He was started on gemcitabine and docetaxel and, after two cycles, remission of all clinical signs occurred over 2 months. A complete biochemical response was achieved and angiographic signs of portal hypertension disappeared. He received 18 cycles of therapy and no limiting side effects were observed. More than 2 years after gemcitabine and docetaxel treatment, the patient remains symptom free. Gemcitabine and docetaxel could be a potential therapeutic strategy for this patient. Pediatr Blood Cancer 2009;53:663–665. © 2009 Wiley‐Liss, Inc.